Drugs / 68Ga-aGPC3-scFv/Fab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06383520 | Sep 2023 → Aug 2025 overdue | hepatocellular carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-aGPC3-scFv/Fab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06383520 ↗ |
| Known as | [68Ga]Ga-aGPC3-Fab | “An anti-GPC3 antigen-binding fragment (Fab) was generated under Good Manufacturing Practice conditions and labeled with Gallium-68 (68Ga) to obtain [68Ga]Ga-aGPC3-Fab.” PMID 41688850 ↗ Feb 2026 |
| Modality | Diagnostic / imaging agent | “GPC3-targeted immunoPET radiotracer” PMID 41688850 ↗ Feb 2026 |